Stay updated on AK104 Plus Anlotinib in NSCLC Clinical Trial
Sign up to get notified when there's something new on the AK104 Plus Anlotinib in NSCLC Clinical Trial page.

Latest updates to the AK104 Plus Anlotinib in NSCLC Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoNo Change Detected
- Check15 days agoChange DetectedThe ClinicalTrials.gov footer revision changed from v3.7.2 to v3.8.0.SummaryDifference0.1%

- Check22 days agoChange DetectedA notice appears announcing NIH website changes and explaining that some federal agency content may use “Super Intelligence” in place of “Artificial Intelligence.”SummaryDifference0.8%

- Check29 days agoChange DetectedThe site footer’s revision identifier changed from v3.7.1 to v3.7.2.SummaryDifference0.1%

- Check36 days agoChange DetectedThe ClinicalTrials.gov site revision changed from v3.7.0 to v3.7.1.SummaryDifference0.1%

- Check57 days agoChange DetectedA new revision entry v3.7.0 has been added to the study's history, while the older revision v3.6.6 has been removed. This indicates ongoing updates to the study record.SummaryDifference0.1%

- Check79 days agoChange DetectedA new site release label Revision: v3.6.6 was added to the history, and the previous label Revision: v3.6.5 was removed, reflecting an update to the release notes shown in the history view.SummaryDifference0.1%

Stay in the know with updates to AK104 Plus Anlotinib in NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the AK104 Plus Anlotinib in NSCLC Clinical Trial page.